Advertisement

Prostaglandins, Cellular Immunity and Cancer

  • James S. Goodwin
  • Jan L. Ceuppens
Chapter
Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 4)

Abstract

This chapter reviews the literature linking prostaglandins (PGs) to the regulation of the cellular immune response, and includes a discussion of the potential for cyclooxygenase inhibitors used as immuno stimulants in cancer. Most of the work on arachidonic acid metabolites in immunity has been concentrated on the role of PGE in the regulation of cellular and humoral immune responses as well as on monocyte and natural killer (NK) cell function. It is not clear that other cyclooxygenase metabolites--thromboxane, prostacyclin, PGF--play a real role in immune responses. More recently, the effects of lipoxygenase products on immune responses has received increasing attention. This review will focus on the evidence linking PGE to control of cellular immune responses.

Keywords

Suppressor Cell Natural Killer Activity Cell Immunol Indomethacin Administration Suppressor Cell Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lum GM, Aisenbrey GA, Dunn RW, Berl RW, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest (59): 8–12, 1977.CrossRefGoogle Scholar
  2. 2.
    Levin RI, Jaffe EA, Weksler BB, Tack-Goldman KT: Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest (67): 762–770, 1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231–238, 1971.Google Scholar
  4. 4.
    Needleman P, Raz A, Ferrendelli JA, Minkes M: Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci (74): 1716–1724, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Gorman RR, Bundy GL, Peterson DC, Sun FF, Miller OV, Fitzpatrick FA: Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Proc Natl Acad Sci (74) : 4007–4013, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR: Arterial walls are protected against deposition of platelet thrombic by a substance (prostaglandin x) which they make from prostaglandin endoperoxides. Prostaglandins (12): 685–691, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Kantor HS, Hampton M: Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase. Nature (London) (276): 841–844, 1978.CrossRefGoogle Scholar
  8. 8.
    Ciosek CP, Ortel RW, Thanassi NM, Newcombe DS: Inhibition of phosphodiesterase by non-steroidal anti-inflammatory drugs. Nature (London) (251): 148–150, 1974.CrossRefGoogle Scholar
  9. 9.
    Webb DR, Osheroff PL: Antigen stimulation of prostaglandin synthesis and control of immune responses. Proc Natl Acad Sci USA (73): 1300–1309, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Goodwin JS, Bankhurst AD, Messner RP: Suppression of human T-cell mitogenesis by prostaglandin; existence of a prostaglandin-producing suppressor cell. J Exp Med (146): 1719–1734, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Whisler RL, Newhouse VG: Inhibition of human B lymphocyte colony responses by endogenous synthesized hydrogen peroxide and prostaglandins. Cell Immunol (69) : 34–45, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    Eckles DD, Gershwin ME: Pharmacologic and biochemical production of human T-lymphocyte colony formation: hormonal influences. Immunopharmacology (3) : 259–274, 1981.CrossRefGoogle Scholar
  13. 13.
    Goodwin JS, Messner RP, Peake GT: Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. J Clin Invest (62) : 753–760, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Gaut ZN, Baruth H, Randall LO, Ashley C, Paulsrud JR: Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins (10) : 59–65, 1975.PubMedGoogle Scholar
  15. 15.
    Goodwin JS, Messner RP, Williams RC Jr: Inhibitors of T-cell mitogenesis: effect of mitogen dose. Cell Immunol (45) : 303–309, 1979.PubMedCrossRefGoogle Scholar
  16. 16.
    Robinson DR, Levine L: Prostaglandin concentrations in synovial fluid in rheumatic diseases: action of indomethacin and aspirin. In: Robinson HJ, Vane JR (eds) Prostaglandin synthetase inhibitors-their effects on physiological functions and pathological states (symposium). Raven Press, New York, 1974, pp 223–228.Google Scholar
  17. 17.
    Novagrodsky A, Rubin AL, Stenzel KH: Selective suppression by adherent cells, prostaglandin, and cyclic AMP analogues of blastogenesis induced by different mitogens. J Immunol (122) : 1–8, 1979.Google Scholar
  18. 18.
    Bockman RS: PGE inhibition of T-lymphocyte colony formation. J Clin Invest (64) : 812–821, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Gorski A, Gaciong, Dupont B: Enhanced colonability of human T lymphocytes caused by their culturing in vitro. Immunology (44) : 617–622, 1982.Google Scholar
  20. 20.
    Muscoplat CC, Klausner DJ, Brunner CJ, Sloane, ED, Johnson DW: Regulation of mitogen-and antigen-stimulated lymphocyte blastogenesis by prostaglandins. Infect Immun (26) : 311–316, 1979.PubMedGoogle Scholar
  21. 21.
    Erten U, Emre T, Cavdar AO, Turker RK: An in vitro study on the effect of prostaglandin E2 and Fla on E-rosette forming activity on normal lymphocytes. Prostaglandins Med (5) : 255–261, 1980.PubMedCrossRefGoogle Scholar
  22. 22.
    Venza-Teti D, Misefari A, Sofo, V, Fimiani V, La Via ML: Interaction between prostaglandins and human T lymphocytes: effect of PGE2 on E-receptor expression. Immunopharmacology (2): 165–171, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Gordon D, Bray M, Morley J: Control of lymphokine secretion by prostaglandins. Nature (262): 401–407, 1976.PubMedCrossRefGoogle Scholar
  24. 24.
    Baker PE, Fahey JV, Munck A: Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol (61): 52–57, 1981.PubMedCrossRefGoogle Scholar
  25. 25.
    Rappaport RS, Dodge GR: Prostaglandin E inhibits the production of human interleukin 2. J Exp Med (155): 943–948, 1982.Google Scholar
  26. 26.
    Soppi E, Eskola J, Ruuskanen O: Effects of indomethacin on lymphocyte proliferation, suppressor cell function, and leukocyte migration inhibitory factor (LMIF) production. Immunopharmacology (4): 2365–2372, 1982.Google Scholar
  27. 27.
    Darrow TL, Tomar RH: Prostaglandin-mediated regulation of the mixed lymphocyte culture and generation of cytotoxic cells. Cell Immunol (65): 172–178, 1980.CrossRefGoogle Scholar
  28. 28.
    Leung KH, Mihich E: Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (288): 597–603, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Van Epps D: Suppression of human lymphocyte migration by PGE2. Inflammation (5): 81–87, 1981.PubMedCrossRefGoogle Scholar
  30. 30.
    Hopkins J, McConnell I, Pearson JD: Lymphocyte traffic through antigen-stimulated lymph nodes. Immunology (42): 225–231, 1981.PubMedGoogle Scholar
  31. 31.
    Tilden AB, Blach CM: A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function. J Immunol (129): 2469–2473, 1982.PubMedGoogle Scholar
  32. 32.
    Chouaib S, Fradelizi D: The mechanism of inhibition of interleukin 2 production. J Immunol (129): 2463–2468, 1982.PubMedGoogle Scholar
  33. 33.
    Wolf M, Droege W: Inhibition of cytotoxic responses by prostaglandin E2 in the presence of interleukin 2. Cell Immunol (72): 286–293, 1982.PubMedCrossRefGoogle Scholar
  34. 34.
    Schultz RM, Stoychkov JN, Pavlidis N, Chirigos MA, Olkowski ZL: Role of E-type prostaglandin in the regulation of interferon-treated macrophage cytotoxic activity. J Reticuloendothel Soc (26): 93–100, 1979.PubMedGoogle Scholar
  35. 35.
    Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (124): 2682–2688, 1980.PubMedGoogle Scholar
  36. 36.
    Garovoy MR, Strom RB, Kaliner M, Carpenter CB: Antibody-dependent lymphocyte mediated cytotoxicity mechanism and modulation by cyclic nucleotides. Cell Immunol (20): 197–205, 1975.PubMedCrossRefGoogle Scholar
  37. 37.
    Trofatter KF Jr, Daniels CA: Interaction of human cells with prostaglandins and cyclic AMP modulators. I. Effects on complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes simplex virus-infected human fibroblasts. J Immunol (122): 1363–1370, 1979.PubMedGoogle Scholar
  38. 38.
    Droller MJ, Schneider MU, Perlmann P: A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol (39): 165–172, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    Targan S: The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and blockage of pre-NK cell recruitment. J Immunol (127): 1424–1430, 1981.PubMedGoogle Scholar
  40. 40.
    Kingston A, Kay JE, Ivanyi J: The effect of prostaglandin E2 and 12-analogues on mitogen induced lymphocyte stimulation. Int J Immunopharmacol (2): 243–250, 1980.CrossRefGoogle Scholar
  41. 41.
    Gordon D, Henderson DC, Westwick J: Effects of prostaglandins E2 and I2 on human lymphocyte transformation in the presence and absence of inhibitors of prostaglandin biosynthesis. Br J Pharmacol (67): 17–20, 1979.PubMedGoogle Scholar
  42. 42.
    Kelly JP, Johnson MC, Parker CW: Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol (122): 1563–1559, 1979.PubMedGoogle Scholar
  43. 43.
    Leung K, Mihich E: Modulation of cell-mediated immunity of prostaglandin synthesis. Int J Immunopharmacol (2): 244–249, 1980.CrossRefGoogle Scholar
  44. 44.
    Gordon D, Novri A, Thomas R: Selective inhibition of thromboxane biosynthesis in human blood mononuclear cells and the effects on mitogen-stimulated lymphocyte proliferation. Immunology (42): 472–478, 1981.Google Scholar
  45. 45.
    Gualde N, Rabinovitch H, Fredon M, Rigaud M: Effects of 15-hydroperoxyeicosatetraenoic acid on human lymphocyte sheep erythrocyte rosette formation and response to concanavalin A associated with HLA system. Eur J Immunol (12): 773–777, 1982.PubMedCrossRefGoogle Scholar
  46. 46.
    Goetzl E, Payan DG, Goetzl EJ: Specific suppression of human T lymphocyte function by leukotriene B4. J Immunol (131): 551–553, 1983.PubMedGoogle Scholar
  47. 47.
    Kennedy MS, Stobo JD, Goldyne ME: In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins (20): 135–141, 1980.PubMedCrossRefGoogle Scholar
  48. 48.
    Kurland JI, Bockman R: Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med (147): 952–960, 1978.PubMedCrossRefGoogle Scholar
  49. 49.
    Webb DR, Nowowiejski I: Mitogen-induced changes in lymphocyte prostaglandin levels: a signal for the induction of suppressor cell activity. Cell Immunol (41): 72–78, 1978.PubMedCrossRefGoogle Scholar
  50. 50.
    Passwell JH, Dayer JM, Merler E: Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (123): 115–121, 1979.PubMedGoogle Scholar
  51. 51.
    Humes JL, Bonney RJ, Pelus L, Dahlgren ME, Sadowski SJ, Kuehl FA Jr, Davies P: Macrophages synthesise and release prostaglandins in response to inflammatory stimuli. Nature (269): 149–150, 1977.PubMedCrossRefGoogle Scholar
  52. 52.
    Ellner JJ, Spagnvolo PJ: Suppression of antigen and mitogen induced human T lymphocyte DNA synthesis by bacterial lipopolysaccharide; mediation by monocyte activation and production of prostaglandins. J Immunol (123): 2689–2695, 1979.PubMedGoogle Scholar
  53. 53.
    Fuse A, Mahmud I, Kuwata T: Mechanism of stimulation by interferon of prostaglandin synthesis in human cell lines. Cancer Res (42): 3209–3214, 1982.PubMedGoogle Scholar
  54. 54.
    Bonney RJ, Naruns PP, Davies P, Humes JL: Antigen-antibody complexes stimulate the synthesis and release of prostaglandins by mouse peritoneal macrophages. Prostaglandins (18): 605–610, 1979.PubMedCrossRefGoogle Scholar
  55. 55.
    Catanzaro A: Suppressor cells in coccidiomycosis. Cell Immunol (64): 235–245, 1981.PubMedCrossRefGoogle Scholar
  56. 56.
    Kaneene J, Anderson R, Johnson DW, Muscoplat CC: Brucella antigen preparations for in vitro lymphocyte immunostimulation assays for bovine Brucellosis. Infect Immun (22): 486–491, 1978.PubMedGoogle Scholar
  57. 57.
    Dore-Duffy P, Zurier RB: Lymphocyte adherence in multiple sclerosis. Role of monocytes and increased sensitivity of MS lymphocytes to prostaglandin El. Clin Immunol Immunopathol (19): 303–313, 1981.PubMedCrossRefGoogle Scholar
  58. 58.
    Wolinsky S, Goodwin JS, Messner RP, Williams RC Jr: Role of prostaglandin in the depressed cell-mediated immune response in rheumatoid arthritis. Clin Immunol Immunopathol (17): 31–36, 1980.PubMedCrossRefGoogle Scholar
  59. 59.
    Panayi GS, Corrigal V, Youlten LJF: Immunoregulation in the rheumatic diseases. Scand J Rheumatol (38): 9–15, 1980.Google Scholar
  60. 60.
    Chinen Y, Nagaoka K, Sakurami T, Imura H: Depression of lymphocyte blastogenesis in steroid-treated rheumatoid arthritis. Arthritis Rheum (25): 713–717, 1982.PubMedCrossRefGoogle Scholar
  61. 61.
    Seitz M, Deimann W, Gram N, Hunstein W, Gemsa D: Characterization of blood mononuclear cells of rheumatoid arthritis patients. Clin Immunol Immunopathol (25): 405–416, 1982.PubMedCrossRefGoogle Scholar
  62. 62.
    Scott PA, Farrell JP: Experimental cutaneous leishmaniasis. J Immunol (127): 2395–2400, 1981.PubMedGoogle Scholar
  63. 63.
    Garin EH, Barratt TM: Effect of indomethacin on lymphocyte response to mitogens in puromycin aminonucleoside nephrosis in the rat. Clin Exp Immunol (49): 639–644, 1982.PubMedGoogle Scholar
  64. 64.
    Kleinhenz ME, Ellner JJ, Spagnuolo PJ, Daniel TM: Suppression of lymphocyte responses by tuberculous plasma and mycobacterial arabinogalactan. J Clin Invest (68): 153–162, 1981.PubMedCrossRefGoogle Scholar
  65. 65.
    Phung ND, Davidson PT: Increased suppressor cell activity in a patient with mycobacterium avium-intracellular pulmonary disease and hypogammaglobulinemia. Ann Allergy (46): 204–207, 1981.PubMedGoogle Scholar
  66. 66.
    Mason UG, Grenberg LE, Yen SS, Kirkpatrick CH: Indomethacinresponse mononuclear cell dysfunction in ‘atypical’ mycobacteriosis. Cell Immunol (71): 54–65, 1982.PubMedCrossRefGoogle Scholar
  67. 67.
    Koster F, Williams J, Goodwin JS: Specific immunologic unresponsiveness in disseminated Q fever: participation of a T cell--monocyte suppressor circuit. Submitted for publication.Google Scholar
  68. 68.
    Kierszenbaum F: Immunologic deficiency during experimental Chagas’ disease (trypanosoma cruzi infection). J Immunol (129): 2202–2205, 1982.PubMedGoogle Scholar
  69. 69.
    Piessens WF, Partono F, Hoffman SL, Ratiwayanto S, Piessens PW, Palmieri JR, Koiman I, Dennis DT, Carney WP: Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med (307): 144–148, 1982.PubMedCrossRefGoogle Scholar
  70. 70.
    Goodwin JS, De Horatius R, Israel H, Peake GT, Messner RP: Suppressor cell function in sarcoidosis. Ann Intern Med (90): 169–175, 1979.PubMedGoogle Scholar
  71. 71.
    Rice L, Laughter A, Twomey J: Three suppressor systems in human blood that modulate lymphoproliferation. J Immunol (122): 991–999, 1979.PubMedGoogle Scholar
  72. 72.
    Drysdale B-E, Shin HS: Activation of macrophages for tumor cell cytotoxicity: identification of indomethacin sensitive and insensitive pathways. J Immunol (127): 760–765, 1981.PubMedGoogle Scholar
  73. 73.
    Zighelbolm J, Lichtenstein A, Benjamin D: Response of normal subjects to mitogens: influence of adherent cells. Clin Immunol Immunopathol (19): 406–415, 1981.CrossRefGoogle Scholar
  74. 74.
    Metzger A, Hoffeld J, Oppenheim J: Macrophage mediated suppression. J Immunol (124): 983–988, 1980.PubMedGoogle Scholar
  75. 75.
    Lapp WS, Mendes M, Kirchner H, Gemsa D: Prostaglandin synthesis by lymphoid tissue of mice experiencing a graftversus-host reaction. Cell Immunol (50): 271–281, 1980.PubMedCrossRefGoogle Scholar
  76. 76.
    Hopkins J, McConnell I, Raniwalla J: Antigen-induced nonspecific suppressor factor in sheep efferent lymph is prostaglandin E2. Immunology (43): 205–210, 1981.PubMedGoogle Scholar
  77. 77.
    Thomas JM, Carver FM, Haisch CE, Fahrenbruch G, Deepe RM, Thomas FT: Suppressor cells in rhesus monkeys treated with antithymocyte globulin. Transplantation (34): 83–89, 1982.PubMedCrossRefGoogle Scholar
  78. 78.
    Staszak CS, Goodwin JS, Troup GM, Rathak DR, Williams RC Jr: Decreased sensitivity to prostaglandin and histamine in lymphocytes from normal HLA-B12 individuals: a possible role in autoimmunity. J Immunol (125): 181–188, 1980.PubMedGoogle Scholar
  79. 79.
    Kirby PJ, Morley, J, Ponsford JR, MacDonald WI: Defective PGE reactivity in leucocytes of multiple sclerosis patients. Prostaglandins (11): 621–626, 1976.PubMedCrossRefGoogle Scholar
  80. 80.
    Goodwin JS, Messner RP: Prostaglandin E inhibition of mitogen stimulation in patients with multiple sclerosis. Prostaglandins (15): 281–287, 1978.Google Scholar
  81. 81.
    Dore-Duffy P, Zurier RB: Lymphocyte adherence in multiple sclerosis: effect of aspirin. J Clin Invest (63): 154–159, 1979.PubMedCrossRefGoogle Scholar
  82. 82.
    Page RC, Clagett JA, Engel LD, Wilde G, Sims T: Effects of prostaglandin on the antigen-and mitogen-driven responses of peripheral blood lymphocytes from patients with adult and juvenile periodonitis. Clin Immunol Immunopathol (11): 77–82, 1978.PubMedCrossRefGoogle Scholar
  83. 83.
    Goodwin JS, Messner RP: Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70. J Clin Invest (64): 434–440, 1979.PubMedCrossRefGoogle Scholar
  84. 84.
    Goodwin JS: Changes in lymphocyte sensitivity to prostaglandin E, histamine, hydrocortisone and x-irradiation with age: studies in a healthy elderly population. Clin Immunol Immunopathol (25): 243–251, 1982.PubMedCrossRefGoogle Scholar
  85. 85.
    Goodwin JS: Increased sensitivity to prostaglandin E2 in old people. Prostaglandins Med (3): 395–401, 1979.PubMedCrossRefGoogle Scholar
  86. 86.
    Delfraissy JF, Garanand P, Wallon C, Balavoine JF, Dormont J: Abolished in vitro antibody response in elderly: exclusive involvement of prostaglandin-induced T suppressor cells. Clin Immunol Immunopathol (24): 377–385, 1982.PubMedCrossRefGoogle Scholar
  87. 87.
    Ceuppens J, Goodwin JS: Endogenous prostaglandin E2 enhances polyclonal immunoglobulin production by tonically inhibiting T suppressor cell activity. Cell Immunol (70): 41–54, 1982.PubMedCrossRefGoogle Scholar
  88. 88.
    Goldberg EH, Frikke MJ: The role of suppressor cells in the fetal escape of maternal immunologic rejection. In: Goodwin JS (ed) Suppressor cells in human disease. Marcel Dekker, New York, 1981, pp 247–266.Google Scholar
  89. 89.
    Olding LB, Benirschke K, Oldstone M: Inhibition of mitosis of lymphocytes from human adults by lymphocytes from human newborns. Clin Immunol Immunopathol (3): 79–88, 1974.PubMedCrossRefGoogle Scholar
  90. 90.
    Olding LB, Oldstone M: Thymus-derived peripheral lymphocytes from human newborns inhibit division of their mother’s lymphocytes. J Immunol (116): 682–687, 1976.PubMedGoogle Scholar
  91. 91.
    Johnsen S, Olding LB, Westberg NG, Wilhelmsson L: Strong suppression by mononuclear leukocytes from human newborns on material leukocytes: mediation by prostaglandins. Clin Immunol Immunopathol (23): 606–615, 1982.PubMedCrossRefGoogle Scholar
  92. 92.
    Goodwin JS, Messner RP, Peake GT: Increased sensitivity of maternal lymphocytes to PGE2. Clin Res (26): 514A, 1978.Google Scholar
  93. 93.
    Vanderbeeken Y, Vlieghe MP, Delespesse G: Regulation of the lymphocyte response to phytohemagglutinin during pregnancy: role of adherent cells and prostaglandins. Am J Reproduct Immunol (1): 233–235, 1981.Google Scholar
  94. 94.
    Goodwin JS, Bromberg S, Staszak C, Kaszubowski PA, Messner RP, Neal JF: Effect of physical stress on sensitivity of lymphocytes to inhibition by prostaglandin E2. J Immunol (127): 518–522, 1981.PubMedGoogle Scholar
  95. 95.
    Wang BS, Heacock EH, Mannick JA: Characterization of suppressor cells generated in mice after surgical trauma. Clin Immunol Immunopathol (24): 161–170, 1982.PubMedCrossRefGoogle Scholar
  96. 96.
    Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB: Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. J Immunol (131): 768–772, 1983.PubMedGoogle Scholar
  97. 97.
    Goodwin JS, Ceuppens JL, Rodriguez MA: Effect of nonsteroidal antiinflammatory agents on immunologic function in patients with rheumatoid arthritis. J Am Med Assoc (250): 2485–2489, 1983.CrossRefGoogle Scholar
  98. 98.
    Ceuppens JL, Goodwin JS: Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet (1): 528–533, 1982.PubMedCrossRefGoogle Scholar
  99. 99.
    Kelly RH, Miller DH, Rodnan GP, Hagmann J: Prostaglandin-mediated inhibition of lymphokine secretion in normal individuals and patients with progressive systemic sclerosis (scleroderma, PSS). Agents Actions (12): 471–477, 1982.PubMedCrossRefGoogle Scholar
  100. 100.
    Taffet S, Russell SW: Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E. J Immunol (126): 424–429, 1981.Google Scholar
  101. 101.
    Goodwin JS, Bankhurst AD, Murphy S, Selinger DS, Messner RP, Williams RC Jr: Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin. J Clin Lab Immunol (1): 197–204,1978.PubMedGoogle Scholar
  102. 102.
    Muscoplat CC, Rakich PM, Thoen CO, Johnson DW: Enhancement of lymphocyte blastogenic and delayed hypersensitivity skin responses by indomethacin. Infect Immun (20): 627–632, 1978.PubMedGoogle Scholar
  103. 103.
    Lipsmeyer E: Effect of cimetidine and indomethacin on delayed hypersensitivity. Transplantation (33): 107–113, 1982.PubMedCrossRefGoogle Scholar
  104. 104.
    Anderson CB, Jaffee BM, Graff RJ: Prolongation of murine skin allografts by prostaglandin El. Transplantation (23): 444–449, 1977.PubMedCrossRefGoogle Scholar
  105. 105.
    Blyth WA, Hill TJ, Field HJ, Harbour DA: Reactivation of herpes simplex virus infection of prostaglandins. J Gen Virol (33): 547–551, 1976.PubMedCrossRefGoogle Scholar
  106. 106.
    Tracey DE, Adkinson NF: Prostaglandin synthesis inhibitors potentiate the BCG-induced augmentation of natural killer cell activity. J Immunol (125): 136–141, 1980.PubMedGoogle Scholar
  107. 107.
    Goodwin JS, Selinger DS, Messner RP, Reed WP: Effect of indomethacin in vivo on humoral and cellular immunity in humans. Infect Immun (19): 430–437, 1978.PubMedGoogle Scholar
  108. 108.
    Grohmann P, Porzsolt F, Quirt I, Miller R, Phillips R: Stimulation of human NK cell activity by cultured cells. Clin Exp Immunol (44): 611–614, 1981.PubMedGoogle Scholar
  109. 109.
    Palmer DG, Barbezat GO, Gibbins BL, Grennan DM, Lum J, Myers DB, Wilson K: A single-blind crossover trial of the anti-inflammatory drug sodium meclofenamate and placebo, including an evaluation of hand grip and of lymphocyte responsiveness. Curr Med Res Opin (7): 359–367, 1981.PubMedGoogle Scholar
  110. 110.
    Palmer DG, Ferry DG, Gibbins BL, Hall SM, Grennan DM, Lum J, Myers DB: Ibuprofen and diflunisal in rheumatoid arthritis: a double-blind comparative trial. NZ Med J (94): 45–47, 1981.Google Scholar
  111. 111.
    Bach MA, Fournier C, Bach JF: Regulation of theta-antigen expression by agents altering cyclic AMP level and by thymic factor. Ann NY Acad Sci (249): 316–320, 1975.PubMedCrossRefGoogle Scholar
  112. 112.
    Gualde N, Rigaud M, Bach JF: Stimulation of prostaglandin synthesis by the serum factor (FTS). Cell Immunol (70): 362–366, 1982.PubMedCrossRefGoogle Scholar
  113. 113.
    Rinaldi-Garaci C, Del Gobbo V, Favalli C, Garaci E, Bistoni F, Jaffe BM: Induction of serum thymic-like activity in adult thymectomized mice by a synthetic analog of PGE2. Cell Immunol (72): 97–101, 1982.PubMedCrossRefGoogle Scholar
  114. 114.
    Burchiel SW, Warner NL: Cyclic AMP modulation of Fc receptor expression on a pre-B cell lymphoma. J Immunol (124): 1016–1021, 1980.PubMedGoogle Scholar
  115. 115.
    Offner H, Danneskiold-Samsoe B, Dore-Duffy P: Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis. Clin Immunol Immunopathol (22): 159–165, 1982.PubMedCrossRefGoogle Scholar
  116. 116.
    Stobo JD, Kennedy MS, Goldyne ME: Prostaglandin E modulation of the mitogenic response of human T cells. J Clin Invest (64): 1188–1192, 1979.Google Scholar
  117. 117.
    Gualde N, Goodwin JS: Effects of prostaglandin E2 and pre-incubation on lectin-stimulated proliferation of human T cell subsets. Cell Immunol (70): 373–378, 1982.PubMedCrossRefGoogle Scholar
  118. 118.
    Kendall R, Targan S: The dual effect of prostaglandin and ethanol on the natural killer cytolytic process. J Immunol (125): 2770–2777, 1980.PubMedGoogle Scholar
  119. 119.
    Schultz RM, Pavlidis NA, Stylos WA, Chirigos MA: Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series. Science (202): 320–327, 1978.Google Scholar
  120. 120.
    McCarthy ME, Zwilling BS: Differential effects of prostaglandins on the antitumor activity of normal and BCG-activated macrophages. Cell Immunol (60): 91–97, 1981.PubMedCrossRefGoogle Scholar
  121. 121.
    Schnyder J, Dewald B, Baggiolini M: Effects of cyclooxygenase inhibitors and prostaglandin E2 macrophage activation in vitro. Prostaglandins (22): 411–416, 1979.CrossRefGoogle Scholar
  122. 122.
    Razin E, Bauminger S, Globerson A: Effect of prostaglandins on phagocytes of sheep erythrocytes by mouse peritoneal macrophages. J Reticuloendothel Soc (23): 237–242, 1978.PubMedGoogle Scholar
  123. 123.
    Wahl LM, Olsen CE, Wahl SM, McCarthy JB, Sandberg AL, Mergenhagen SE: Prostaglandin and cyclic AMP regulation of macrophage involvement in connective tissue destruction. Ann NY Acad Sci (332): 271–278, 1979.PubMedCrossRefGoogle Scholar
  124. 124.
    Smith JW, Steiner AL, Parker CW: Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest (50): 442–449, 1971.PubMedCrossRefGoogle Scholar
  125. 125.
    Melmon KL, Bourne HR, Weinstein Y, Shearer GM, Kram J, Bauminger S: Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones. J Clin Invest (53): 22–27, 1974.PubMedCrossRefGoogle Scholar
  126. 126.
    Goodwin JS, Wiik A, Lewis M, Bankhurst AD, Williams RC Jr: High affinity binding sites for prostaglandin E on human lymphocytes. Cell Immunol (43): 150–159, 1979.CrossRefGoogle Scholar
  127. 127.
    Kalmar L, Gergely P: Enhancement of mitogen-induced lymphocyte proliferation after preincubation is due to altered sensitivity to prostaglandins. Immunol Lett (4): 179–183, 1982.PubMedCrossRefGoogle Scholar
  128. 128.
    Goodwin JS, Bromberg S, Messner RP: Studies on the cyclic AMP response to prostaglandin in human lymphocytes. Cell Immunol (60): 298–307, 1981.PubMedCrossRefGoogle Scholar
  129. 129.
    Webb DR, Rogers TJ, Ong S, Steiner A: Detection of prostaglandin induced antigen-stimulated changes in splenic AMP levels by immunofluorescence. Prostaglandins Med (5): 141–147, 1980.PubMedCrossRefGoogle Scholar
  130. 130.
    Goodwin JS, Kaszubowski PA, Williams RC Jr: Cyclic adenosine monophosphate response to prostaglandin E2 in subpopulations of human lymphocytes. J Exp Med (150): 1260–1267, 1979.PubMedCrossRefGoogle Scholar
  131. 131.
    Moretta L, Webb SR, Grossi CE, Lydyard PM, Cooper MD: Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T-cells bearing receptors for IgM or IgG. J Exp Med (146): 184–200, 1977.PubMedCrossRefGoogle Scholar
  132. 132.
    Pelus C, Bockman R: Increased prostaglandin synthesis by microphages from tumor bearing mice. J Immunol (123): 2118–2124, 1979.PubMedGoogle Scholar
  133. 133.
    Glaser M: Indomethacin-sensitive suppressor cells regulate the cell-mediated cytotoxic response to SV 40-induced tumor-associated antigens in mice. Eur J Immunol (10): 489–496, 1980.PubMedCrossRefGoogle Scholar
  134. 134.
    Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC Jr: Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med (197): 263–269, 1977.Google Scholar
  135. 135.
    Bockman RS: Stage dependent reduction in T-colony formation in Hodgkin’s disease. J Clin Invest (66): 523–531, 1980.PubMedCrossRefGoogle Scholar
  136. 136.
    DeShazo RP: Indomethacin-responsive mononuclear cell dysfunction in Hodgkin’s disease. Clin Immunol Immunopathol (17) : 66–72, 1980.PubMedCrossRefGoogle Scholar
  137. 137.
    Sibbitt WL Jr, Bankhurst AD, Williams RC Jr: Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin’s disease. J Clin Invest (61) : 55–63, 1978.PubMedCrossRefGoogle Scholar
  138. 138.
    Johnsen SA: Prostaglandin associated immunosuppression. Doctoral thesis, University of Gateborg, Sweden, 1983.Google Scholar
  139. 139.
    Bankhurst AD, Kauffman G, Goodwin JS, Williams RC Jr: Suppressor leukocytes in anergic patients with solid tumors. J Lab Clin Immunol (3): 3–10, 1980.Google Scholar
  140. 140.
    Vosixa G, Thies J: Effect of indomethacin on blastogenesis of lymphocytes from cancer patients: differentiation of patient types. Clin Immunol Immunopathol (13): 30–36, 1979.PubMedCrossRefGoogle Scholar
  141. 141.
    Maca RD, Panje W: Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre and post irradiation therapy. Cancer (50): 438–489, 1982.CrossRefGoogle Scholar
  142. 142.
    Balch CM, Dougherty PA, Tilden A: Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg (196): 645–650, 1982.PubMedCrossRefGoogle Scholar
  143. 143.
    Braun DP, Harris JE: Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst (67) : 809–814, 1981.PubMedGoogle Scholar
  144. 144.
    Klein DC, Raisl LG: Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology (86): 1436–1443, 1970.PubMedCrossRefGoogle Scholar
  145. 145.
    Bennett A, Del Tacca M, Stamford IF, Zebro T: Prostaglandins from tumours of human large bowel. Br J Cancer (35): 881–884, 1977.PubMedCrossRefGoogle Scholar
  146. 146.
    Cummings KB, Robertson RP: Prostaglandin: increased production by renal cell carcinoma. J Urol (118) : 720–727, 1977.PubMedGoogle Scholar
  147. 147.
    Husby G, Strickland RG, Rigler GL, Peake GT, Williams RC Jr: Direct immunochemical detection of prostaglandin E and cyclic nucleotides in human malignant tumors. Cancer (40): 1629–1636, 1977.Google Scholar
  148. 148.
    Powles TJ, Coomes RC, Neville AM, Ford HT, Gazet JC, Levine L: 15-keto-13, 14 dihydroprostaglandin E2 concentrations in serum of patients with breast cancer. Lancet (2): 138–143, 1977.PubMedCrossRefGoogle Scholar
  149. 149.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst (64): 1061–1068, 1980.PubMedGoogle Scholar
  150. 150.
    Sykes JAC, Maddox IS: Prostaglandin production by experimental tumours and effects of anti-inflammatory compounds. Nature New Biology (237): 59–61, 1972.PubMedCrossRefGoogle Scholar
  151. 151.
    Tashjian AH, Voelkel EF, Levine L, Goldhaber P: Evidence that the bone-resorption stimulating factor produced by mouse fibrosarcoma cells is prostaglandin. J Exp Med (136): 1329–1336, 1972.PubMedCrossRefGoogle Scholar
  152. 152.
    Owen K, Gomolka D, Droller MJ: Lymphocyte induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. Cell Immunol (55): 428–435, 1980.PubMedCrossRefGoogle Scholar
  153. 153.
    Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci (72): 1848–1854, 1975.PubMedCrossRefGoogle Scholar
  154. 154.
    Grinwich KD, Plescia OJ: Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis. Prostaglandins (14): 1175–1183, 1977.PubMedCrossRefGoogle Scholar
  155. 155.
    Hial V, Horakova Z, Shaff FE, Beaven MA: Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol (37): 367–376, 1976.PubMedCrossRefGoogle Scholar
  156. 156.
    Lynch NR, Casatles M, Astonin M, Salomon JC: Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br J Cancer (38): 503–509, 1978.PubMedCrossRefGoogle Scholar
  157. 157.
    Humes JL, Cupo J, Strausser, HR: Effects of indomethacin on Moloney sarcoma virus-induced tumors. Prostaglandins (6) : 463–469, 1974.PubMedCrossRefGoogle Scholar
  158. 158.
    Strausser HR, Humes JL: Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in mice. Int J Cancer (15) : 724–729, 1975.PubMedCrossRefGoogle Scholar
  159. 159.
    Bennett A, Houghton J, Leaper DJ, Stamford IF: Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins (17) : 179–191, 1979.PubMedCrossRefGoogle Scholar
  160. 160.
    Pollard M, Luckert, PH: Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science (214): 558–559, 1981.PubMedCrossRefGoogle Scholar
  161. 161.
    Waddell WR, Gerner RE, Reich MD: Nonsteroid antiinflammatory drugs for desmoid tumors and carcinoma of the stomach, submitted for publication, 1982.Google Scholar
  162. 162.
    Panje WR: Regression of head and neck carcinoma with a prostaglandin synthesis inhibitor. Arch Otolaryngol (107): 658–663, 1981.PubMedGoogle Scholar
  163. 163.
    Galasko CSB, Bennett A: A relationship of bone distinction in skeletal metastases to osteoclast activation and prostaglandins. Nature (263): 508–513, 1976.PubMedCrossRefGoogle Scholar
  164. 164.
    Powles TJ, Clar SA, Easty DM, Easty CG, Neville AM: The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (28): 316–321, 1973.PubMedCrossRefGoogle Scholar
  165. 165.
    Yoneda R, Mundy GR: Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes. J Exp Med (149): 279–288, 1979.PubMedCrossRefGoogle Scholar
  166. 166.
    Lupulescu A: Enhancement of carcinogenesis by prostaglandins in male, albino Swiss mice. J Natl Cancer Inst (61): 97103, 1978.Google Scholar
  167. 167.
    Levine L, Ohucki K: Retinoids as well as tumor promoters enhance deacylation of cellular lipids and prostaglandin production in MDCK cells. Nature (276) : 274–280, 1978.PubMedCrossRefGoogle Scholar
  168. 168.
    Ohuchi K, Levine L: Stimulation of prostaglandin synthesis by tumor-promoting phorbol-12–13-diesters in canine kidney (MDCK) cells. J Biol Chem (253) : 4783–4790, 1978.PubMedGoogle Scholar
  169. 169.
    Yamasaki H, Mufson RA, Weinstein IB: Phorbol ester induced prostaglandin synthesis and [3H]-TPA metabolism by TPA-sensitive and TPA-resistant friend erythroleukemia cells. Biochem Biophys Res Commun (89): 1018–1025, 1979.PubMedCrossRefGoogle Scholar
  170. 170.
    Buick RN, Fry SE, Salmon SE: Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer (41): 695–704, 1980.PubMedCrossRefGoogle Scholar
  171. 171.
    Santoro MG, Philpott GW, Jaffe BM: Inhibition of tumor growth in vivo and in vitro by prostaglandin E. Nature (263): 777–779, 1976.CrossRefGoogle Scholar
  172. 172.
    Stringfellow D, Fitzpatrick F: Prostaglandin Da controls pulmonary metastasis of malignant melanoma cells. Nature (282): 76–84, 1979.PubMedCrossRefGoogle Scholar
  173. 173.
    Favalli C, Garaci E, Etheredge E, Santoro MG, Jaffe BM: Influence of PGE in the immune response in melanoma-bearing mice. J Immunol (125): 897–906, 1980.PubMedGoogle Scholar
  174. 174.
    Hofer D, Dubitsky AM, Reilly P, Santoro MG, Jaffe BM: The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. Prostaglandins (20): 1033–1038, 1980.PubMedCrossRefGoogle Scholar
  175. 175.
    Santoro MG, Jaffe, BM: Inhibition of friend erythroleukemiacell tumors in vivo by a synthetic analogue of prostaglandin E2. Br J Cancer (39): 408–413, 1979.PubMedCrossRefGoogle Scholar
  176. 176.
    Karmali RA, Horrobin DF, Menenzes J, Patel P: The relationship between concentrations of prostaglandin Al, El, E2 and E2 alpha and rates of cell proliferation. Pharmacol Res Commun (11): 69–76, 1979.PubMedCrossRefGoogle Scholar
  177. 177.
    Klimpel GR: Soluble factors from BCG-induced suppressor cells inhibit in vitro PFC responses but not cytotoxic responses. Cell Immunol (47): 218–226, 1979.PubMedCrossRefGoogle Scholar
  178. 178.
    Klimpel G, Henney CS: BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T-cell generation in vitro. J Immunol (120): 563–570, 1978.PubMedGoogle Scholar
  179. 179.
    Klimpel GR, Okada M, Henney CS: Inhibition of in vitro cytotoxic responses by BCG-induced microphage-like suppressor cells. U. Suppression occurs at the level of ‘helper’ T cell. J Immunol (123): 350–357, 1979.PubMedGoogle Scholar
  180. 180.
    Neta R, Slavin, SB: Adjuvants in the induction of suppressor cells. Infect Immun (23): 360–365, 1979.PubMedGoogle Scholar
  181. 181.
    Savary CA, Lotzova E: Suppression of natural killer cell cytotoxicity by splenocytes from corynebacterium parvuminjected bone marrow-tolerant and infant mice. J Immunol (120): 239–245, 1978.PubMedGoogle Scholar
  182. 182.
    Grimm W, Seitz M, Kirchner H, Gemsa D: Prostaglandin synthesis in spleen cell cultures of mice injected with corynebacterium parvum. Cell Immunol (40): 419–426, 1978.PubMedCrossRefGoogle Scholar
  183. 183.
    Wahl SM, Wahl LM, McCarthy JB, Chedid L, Mergenhagen SE: Macrophage activation by mycobacterial water soluble compounds and synthetic maramyl dipeptide. J Immunol (122): 2226–2232, 1979.PubMedGoogle Scholar
  184. 184.
    Lynch NR, Salomon J-C: Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst (62): 117–121, 1979.PubMedGoogle Scholar
  185. 185.
    Droller M, Gomolka D: Interferon expression and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. Cell Immunol (72): 1–13, 1982.PubMedCrossRefGoogle Scholar
  186. 186.
    Droller MA, Gomolka D: Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic-polycytidylic acid. Cancer Res (42): 5038–5045, 1982.PubMedGoogle Scholar
  187. 187.
    Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol (15): 106–122, 1980.PubMedCrossRefGoogle Scholar
  188. 188.
    Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol (3): 295–305, 1984.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • James S. Goodwin
  • Jan L. Ceuppens

There are no affiliations available

Personalised recommendations